Identification of Two Novel Mutations in PKHD1 Gene from Two Families with Polycystic Kidney Disease by Whole Exome Sequencing

Masoud Heidari¹, Hamid Gharshasbi², Alireza Isazadeh³, Morteza Soleyman-Nejad⁴, Mohammad Hossein Taskhiri⁴, Javad Shapouri⁵, Manzar Bolhassani⁴, Nahid Sadighi⁶ and Mansour Heidari⁷*

¹Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran; ²Department of Genetics, Tabriz Branch Islamic Azad University, Tabriz, Iran; ³Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; ⁴Ariagene Medical Genetics Laboratory, Qom, Iran; ⁵Pediatric Clinical Research and Development Center, Qom University of Medical Sciences, Qom, Iran; ⁶Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences (TUMS), Tehran, Iran; ⁷Department of Medical Genetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Abstract: Background: Polycystic kidney disease (PKD) is an autosomal recessive disorder resulting from mutations in the PKHD1 gene on chromosome 6 (6p12), a large gene spanning 470 kb of genomic DNA.

Objective: The aim of the present study was to report newly identified mutations in the PKHD1 gene in two Iranian families with PKD.

Materials and Methods: Genetic alterations of a 3-month-old boy and a 27-year-old girl with PKD were evaluated using whole-exome sequencing. The PCR direct sequencing was performed to analyse the co-segregation of the variants with the disease in the family. Finally, the molecular function of the identified novel mutations was evaluated by in silico study.

Results: In the 3-month-old boy, a novel homozygous frameshift mutation was detected in the PKHD1 gene, which can cause PKD. Moreover, we identified three novel heterozygous missense mutations in ATIC, VPS13B, and TP53RK genes. In the 27-year-old woman, with two recurrent abortions history and two infant mortalities at early weeks due to metabolic and/or renal disease, we detected a novel missense mutation on PKHD1 gene and a novel mutation in ETFDH gene.

Conclusion: In general, we have identified two novel mutations in the PKHD1 gene. These molecular findings can help accurately correlate genotype and phenotype in families with such disease in order to reduce patient births through preoperative genetic diagnosis or better management of disorders.

Keywords: Polycystic kidney disease, PKHD1 gene, whole-exome sequencing, mutation, disorder, ETFDH gene.

1. INTRODUCTION

Polycystic kidney disease (PKD) is one of the most prevalent hereditary autosomal recessive disorders in children, including neonates and young people, with 1/6000 to 1/55000 frequency. In the most severe cases, it can be diagnosed prenatally by the presence of enlarged, echogenic kidneys and oligohydramnios [1, 2]. However, in the milder forms, clinical manifestations are usually detected in the neonatal and childhood period.

Various mutations in PKHD1 gene, located on chromosome 6 (6p12) with 75 exons, are associated with this disease. The largest protein product of this gene is called the FPC/polyductin complex (FPC). It is a single-membrane spanning protein whose absence leads to abnormal ciliogenesis in the kidneys [3, 4]. Until now, more than 300 mutations have been identified in different regions of this gene. The most common mutation in PKHD1 gene is a missense mutation in exon 3 (NM_138694.3: p.T36M c.107C>T). With the exception of this mutation, which accounts for approximately one-fifth of the mutations that cause the disease, no other mutation hotspot has been found in this gene. Most of the mutations appear to be unique to one genealogy [4].

Symptoms of PKD are usually present in infancy and have been recognized by clinical presentation in adulthood [5, 6]. The most common manifestations of this disease in infants are a history of oligohydramnios, enlargement of kidneys and pulmonary hypoplasia. Moreover, other organs be-
sides the kidney are also involved in patients with PKD [4, 7]. Although the relationship between genotype and phenotype in this disease is not fully understood, the presence of truncating mutations usually results in a severe form of disease and death in the fetus [4, 8].

In the present study, we identified two novel frameshift and missense mutations in **PKHD1** gene in two different Iranian families with PKD by whole-exome sequencing.

2. MATERIALS AND METHODS

2.1. Patients Presentation

In the present study, two Iranian patients with polycystic kidney disease were referred to Aria Gene Medical Genetics Laboratory (Qom-Iran) in June 2019. The first patient was a 3-month-old boy (the third child of the family) with PKD (IV-1), which was offspring of consanguineous marriages (Fig. 1A). Another child of the family was male and suffered from polycystic kidney disease (IV-2). The second patient was a 27-year-old (III-6) woman with polycystic kidney disease and two recurrent abortions history (IV-3 and IV-4) at early weeks (Fig. 1B). The studied probands showed that various symptoms include potter facies, hypertension, lung hypoplasia, periporal fibrosis, portal hypertension, hepatomegaly, hepatic cysts, pancreatic cysts, bile duct dilatation and proliferation, splenomegaly, esophageal varices, enlarged kidneys, cystic kidneys, renal failure, increased echogenicity of entire parenchyma, loss of corticomedullary differentiation, interstitial fibrosis, dehydration, enlarged kidney splenectomy, and cystic kidneys. According to the ethical standards of the Declaration of Helsinki, the patients and their parents were informed about the study, and informed consent was signed. The study was performed with the approval of the Institutional Review Board (IRB), and informed consent was obtained from patients, or authorized representative/guardian, and before genetic testing. The pedigree of the patients was drawn (Cyrillic 2.1 software) to determine the inheritance pattern of the disease.

2.2. Genomic DNA Extraction and Whole-Exome Sequencing

The peripheral blood sample (5 mL) were taken from studied patients and family members, and added to a tube contains with EDTA as the anticoagulant. Extraction of genomic DNA was performed using DNA purification kit, according to the manufacturer's instructions. The quantity and quality of extracted genomic DNA were investigated using a nanodrop instrument and electrophoresis on 1% agarose, respectively. The whole-exome sequencing was employed to enrich all genomic coding regions and some important other genomic regions. The next-generation sequencing was performed to sequence approximately 100 million reads on Illumina Sequencer (Illumina, San Diego, CA, USA). Bioinformatics analysis of the sequencing results was performed using international databases. Genetic variants such as point mutations and indels were identified using SAMtools and annotated by ANNOVAR software. The candidate genes were considered a variant that fulfilled the following criteria: (i) missense, nonsense, frameshift, and splice-site variants, (ii) absent or rare (frequency below 1%) in the two databases (db SNP, 1000 G), and (iii) homozygous variants in the patient [9].

2.3. Confirmation of Whole Exome Sequencing Results by Sanger Sequencing

The target exons containing mutations of **PKHD1** gene were typically amplified using 10 pmole of primer, 0.2 U Taq DNA polymerase, 200 μM of each dNTPs, 0.67 μl of 50 mM MgCl₂, 60 ng DNA and 2.5 μl of PCR buffer in 25 μl of PCR reactions. The PCR conditions included an initial denaturation step for 3 min at 95°C, 30 sec at 95°C, 30 sec at 60°C with a 1°C at 72°C for 35 cycles, and finally 10 min at 72°C. The PCR products were separated on 2% agarose

---

**Fig. (1).** Pedigree analysis and molecular evaluation of studied patients with ARPKD. A 3 months-old boy with a novel homozygous frameshift mutation in **PKHD1** gene (A). A 27 years-old woman with a novel heterozygous mutation in **PKHD1** gene (B).
gels and visualized Gel Green® stained. Subsequently, to confirm the identified mutation, the PCR products were subjected to direct sequencing. Then, the PCR products were sequenced on an ABI 3130 automated sequencer (Applied Biosystems, Forster City, CA, USA). Sequence data searches were performed in non-redundant nucleic and protein databases BLAST (http://www.ncbi.nlm.nih.gov/BLAST) [10].

3. RESULTS

In the first patient (a 3-month-old boy with polycystic kidney disease), a novel homozygous frameshift mutation was detected in the PKHD1 gene (NM_138694: exon 7: p.H154fs c.460delC), which can cause PKD. In addition, we identified three novel heterozygous missense mutations in ATIC (NM_004044: exon 6: p.R171K c.G512A), VPS13B (NM_017890: exon 61: p.C3916Y c.G11747A), and TP53RK (NM_033550: exon2: p.G253R c.G757A) genes. These mutations were not previously reported, and thus classified as a variation of unknown significance (VUS). In this patient, the four identified mutations in PKHD1 gene were in the homozygous state, whereas their parents were in the heterozygous state.

In the second patient (a 27-years-old woman with polycystic kidney disease and two recurrent abortions history and two infant mortality at early weeks due to metabolic and/or renal disease), we detected a novel missense mutation in PKHD1 gene (NM_138694:6:exon7: p.H2216R c.A6647G) in PKHD1 gene and a novel mutation (MN_004453:3: p.Ser425AegF-sTer3 c.1273-1276derTCAA) in ETFDH gene. These mutations were not previously reported and thus classified as a variation of unknown significance (VUS). In this patient and her husband, the two identified mutations in PKHD1 and ETFDH genes were in the homozygous state, which can cause recurrent abortions and infant mortality.

4. DISCUSSION

PKD is caused by mutations in the PKHD1 gene, which extends over about 470 kb and includes at least 66 exons with a large number of alternatively spliced transcripts. The longest continuous open reading frame encodes a 4074 amino acid protein PKD-causing mutations that have been identified along the entire length of the PKHD1 gene, and multiple mutation types are pathogenic [11]. Approximately, 750 pathogenic mutations have been cataloged in the PKD mutation database (URL), of which half are missense mutations. The most common mutation is a missense mutation in exon 3 (p.T36M c.C107T), which accounts for about 20% of all mutant alleles [12]. In a study on fetuses and neonates with PKD, it was found that after adjusting for gestational age, the extent of the dilatation of the collecting duct, but not portal fibrosis, significantly correlated with the presence of two truncating mutations [13]. In general, patients with two truncating mutations often have a severe phenotype and die in the perinatal stage [14]. However, there are exceptions, for example, it has been reported that a child homozygous for a large PKHD1 deletion was able to survive well past the neonatal period [15]. In addition, patients with the same genotype may also have significantly different phenotypes, suggesting that genetic modifiers modulate disease expression [12].

The multi-domain transmembrane protein fibrocytin/polyductin (FPC) is the protein product encoded by PKHD1 gene. This protein is a single transmembrane-spanning protein with a long extracellular N-terminus and short cytoplasmic tail [16]. The FPC undergoes notch-like proteolytic processes, resulting in the shedding of the extracellular domain into the tubular lumen. Meanwhile, the C-terminal domain translocates into the nucleus for transcription regulation [17]. During embryonic development, the PKHD1 gene is widely expressed in neural tubes, bronchi, primordial guts, and early ureteric buds, mesonephric tubules, adrenal cortex, and immature hepatocytes, which suggests that it plays an important role in organ development and tubular morphogenesis. In adult tissues, the FPC is mainly expressed in kidneys (primarily in collecting ducts and thick ascending loops of Henle), and in ductal epithelial cells of the liver and in the pancreas [16, 18]. FPC is mainly localized to primary cilia and is currently believed to be the “sensation antenna” of kidney epithelial cells or bile duct cells [19]. Incorrect protein structure of FPC leads to loss of polarity in kidney tubular epithelial cells or biliary epithelial cells, and cysts are easily formed.

In the present study, we reported two newly identified mutations in the PKHD1 gene by whole-exome sequencing in two different Iranian patients with polycystic kidney disease. We identified two mutations, (p.H154fs c.460delC) and (p.H2216R c.A6647G) within the coding sequence of PKHD1 in the parents. The unreported mutations of the coding sequence of the PKHD1 gene were confirmed by the Sanger sequencing. According to the published data and Global Variome shared LOVD (https://databases.lovd.nl/shared/genes/PKHD1), these identified variants seem to be novel mutations. These results indicate the high efficiency of the whole-exome sequencing method in detecting various mutations. This is not only an economical means for detection, but also significantly reduces detection time, and gives reliable results. However, it is important to mention that repeat expansion diseases like fragile X, large deletion, duplication and copy number variations, such as Duchene muscular dystrophy, are not detectable by this method.

Since missense mutations are usually associated with a milder disease phenotype, the missense mutation in the second proband (III-6) is consistent with the mild disease phenotype in our study. On the other hand, some mutations that result in complete loss of protein are associated with intrauterine death; the frameshift mutation in the first proband (IV-1) is consistent with the severe disease phenotype. The autosomal recessive inheritance pattern indicates a higher incidence of disease in kinship marriages, given the high incidence rates of the disease in different generations of offspring marriage. Therefore, the genetic examination of patients helps to predict the likelihood of recurrence in families and allows for prenatal diagnosis and preimplantation ge-
netic diagnosis. The genomic regions besides exons of protein-coding genes and mutations in the upstream and downstream regulatory regions have not been investigated, which indicate the limitation of the present study.

CONCLUSION

In conclusion, next-generation sequencing technology and subsequent validation Sanger sequencing is a cost-effective and powerful tool to detect large genes, such as PKHD1. Both reported genetic variants in the PKHD1 gene strongly supported previous studies, and suggested that this gene contains different hotspot regions. However, further studies will be required to clarify the genotype-phenotype correlations in patients with various mutations in the PKHD1 gene.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was performed with the approval of the Institutional Review Board (IRB).

HUMAN AND ANIMAL RIGHTS

No animals were used in this study that are the basis of this research. All procedures performed on humans were in accordance to the ethical standards of the Declaration of Helsinki.

CONSENT FOR PUBLICATION

Informed consent was obtained from the patients.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

The authors would like to thank the patients and their family members who have participated and collaborated with this study.

REFERENCES

[1] Rajanna, D.K.; Reddy, A.; Srinivas, N.S.; Anjara, A. Autosomal recessive polycystic kidney disease: antenatal diagnosis and histopathological correlation. *J. Clin. Imaging Sci.*, 2013, 3, 13. http://dx.doi.org/10.4103/2156-7514.109733 PMID: 23814685

[2] Collins, A.J.; Foley, R.; Herzog, C.; Chavers, B.; Gilbertson, D.; Ishani, A.; Kasiske, B.; Liu, J.; Mau, L.W.; McBean, M.; Murray, A. United States renal data system 2007 annual data report abstract. *Am. J. Kidney Dis.*, 2008, 51(1), A6-A7. http://dx.doi.org/10.1053/j.ajkd.2007.11.001

[3] Onuchic, L.F.; Furu, L.; Nagasawa, Y.; Hou, X.; Eggermann, T.; Ren, Z.; Bergmann, C.; Senderek, J.; Esquivel, E.; Zeltner, R.; Rudnik-Schöneborn, S.; Mrug, M.; Sweeney, W.; Avner, E.D.; Zerres, K.; Guay-Woodford, L.M.; Somlo, S.; Germino, G.G. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. *Am. J. Hum. Genet.*, 2002, 70(5), 1305-1317. http://dx.doi.org/10.1086/340446 PMID: 11898128

[4] Hartung, E.A.; Guay-Woodford, L.M. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. *Pediatrics*, 2014, 134(3), e833-e845. http://dx.doi.org/10.1542/peds.2013-3646 PMID: 25113295

[5] Harris, P.C.; Torres, V.E. Polycystic kidney disease. *Annu. Rev. Med.*, 2009, 60, 331-347. http://dx.doi.org/10.1146/annurev.med.60.101707.125712 PMID: 19847299

[6] Adeva, M.; El-Youssef, M.; Rossetti, S.; Kamath, P.S.; Kubly, V.; Consugar, M.B.; Milliner, D.M.; King, B.F.; Torres, V.E.; Harris, P.C. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). *Medicine (Baltimore)*, 2006, 85(1), 1-21. http://dx.doi.org/10.1097/01.md.0000200165.90373.9a PMID: 16523049

[7] Heidari, M.; Soleyman-Nejad, M.; Taskhiri, M.H.; Shahpour, J.; Iszadadeh, A.; Ahangari, R.; Mohamadi, A.R.; Ebrahimi, M.; Kari- ni, H.; Bolhassani, M.; Karimi, Z.; Heidari, M. Identification of two novel mutations in the JMT gene from patients with ataxia-telangiectasia by whole exome sequencing. *Curr. Genomics*, 2019, 20(7), 531-534. http://dx.doi.org/10.2174/138920291266619107103734 PMID: 32655291

[8] Aref, M.; Dehghani, A.; Iszadadeh, A.; Hajazimian, S.; Mehdizadeh, M.; Raahaei, S.; Hosseini, S.; Kalantari, E. A novel homozygous MYO7A mutation: case report. *Acta Med. Iran.*, 2018, 56(5), 348-350. http://dx.doi.org/10.21740/0138-20292016619107103734 PMID: 32655291

[9] Heidari M, Soleyman-Nejad M, Iszadadeh A, Taskhiri MH, Bolhas- sani M, Sadighi N, Shiri Z, Karimi Z, Heidari M. Identification of a novel homozygous mutation in the DDR2 gene from a patient with spondylo-meta-epiphyseal dysplasia by whole exome sequencing. *Iran J. Basic Med Sci.*, 2021, 24(2), 191-5.

[10] Heidari M, Soleyman-Nejad M, Iszadadeh A, Shapouri J, Taskhiri MH, Ahangari R, Mohamadi AR, Ebrahimi M, Karimi H, Bolhas- sani M, Karimi Z. Association of a novel homozygous mutation in the HMGCS2 gene with an HMGCSD in an Iranian patient. *Mol. Genet. Genom. Med.*, 2020, 8(11), e1507.

[11] Bergmann, C.; Senderek, J.; Sedlacek, B.; Pegiazoglou, I.; Puglia, P.; Eggermann, T.; Rudnik-Schöneborn, S.; Furu, L.; Onuchic, L.F.; De Baca, M.; Germino, G.G.; Guay-Woodford, L.; Somlo, S.; Moser, M.; Büttner, R.; Zerres, K. Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARP KD/ PKHD1). *J. Am. Soc. Nephrol.*, 2003, 14(1), 76-89. http://dx.doi.org/10.1097/01asn.000039578.55705.6e PMID: 12506140

[12] Bergmann, C.; Senderek, J.; Windelen, E.; Küpper, F.; Middeldorff, I.; Schneider, F.; Dormia, C.; Rudnik-Schöneborn, S.; Kon- rad, M.; Schmitt, C.P.; Seeman, T.; Neuhaus, T.J.; Vester, U.; Kir- fel, J.; Büttner, R.; Zerres, K. Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). *Kidney Int.*, 2005, 67(3), 829-848. http://dx.doi.org/10.1111/j.1523-1755.2005.00148.x PMID: 15608423

[13] Denamur, E.; Delezoide, A.L.; Alberti, C.; Bourillon, A.; Gubler, M.C.; Bouvier, R.; Pascual, O.; Elion, J.; Grandchamp, B.; Michel-Calemard, L.; Missy, P.; Zaccaria, I.; Le Nagard, H.; Gerard, B.; Loirat, C.; Barbet, J.; Beaufrère, A.M.; Berchel, C.; Bessières, B.; Boudjemaa, S.; Buender, A.; Carles, D.; Clemen- son, A.; Dechelotte, P.; Desvaux, L.; Dijoud, F.; Espérandieu, O.; Fallet, C.; González, M.; Hillion, Y.; Jacob, B.; Joubert, M.; Ker- manach, P.; Lallemend, A.; Laquerrière, A.; Laurent, N.; Liprandi, A.; Loiullet, L.; Loget, P.; Martinovic, J.; Ménez, F.; Nafey, C.; Roux, J.J.; Rouleau-Dubois, C.; Sinico, M.; Tantau, J.; Wann, A.R. Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease. *Kidney Int.*, 2010, 77(4), 350-358. http://dx.doi.org/10.1038/ki.2009.440 PMID: 19940839
Rossetti, S.; Harris, P.C. Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. *J. Am. Soc. Nephrol.*, 2007, 18(5), 1374-1380. http://dx.doi.org/10.1681/ASN.2007010125 PMID: 17429049

Zvereff, V.; Yao, S.; Ramsey, J.; Mikhail, F.M.; Vijzelaar, R.; Messiaen, L. Identification of PKHD1 multixon deletions using multiplex ligation-dependent probe amplification and quantitative polymerase chain reaction. *Genet. Test. Mol. Biomarkers*, 2010, 14(4), 505-510. http://dx.doi.org/10.1089/gtmb.2009.0188 PMID: 20575693

Menezes, L.F.; Cai, Y.; Nagasawa, Y.; Silva, A.M.; Watkins, M.L.; Da Silva, A.M.; Somlo, S.; Guay-Woodford, L.M.; Germino, G.G.; Onuchic, L.F. Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. *Kidney Int.*, 2004, 66(4), 1345-1355. http://dx.doi.org/10.1111/j.1523-1755.2004.00844.x PMID: 15458427

Kaimori, J.Y.; Nagasawa, Y.; Menezes, L.F.; Garcia-Gonzalez, M.A.; Deng, J.; Imai, E.; Onuchic, L.F.; Guay-Woodford, L.M.; Germino, G.G. Polyductin undergoes notch-like processing and regulated release from primary cilia. *Hum. Mol. Genet.*, 2007, 16(8), 942-956. http://dx.doi.org/10.1093/hmg/ddm039 PMID: 17470460

Bakeberg, J.L.; Tammachote, R.; Woollard, J.R.; Hogan, M.C.; Tuan, H.F.; Li, M.; van Deursen, J.M.; Wu, Y.; Huang, B.Q.; Torres, V.E.; Harris, P.C.; Ward, C.J. Epitope-tagged Pkhd1 tracks the processing, secretion, and localization of fibrocystin. *J. Am. Soc. Nephrol.*, 2011, 22(12), 2266-2277. http://dx.doi.org/10.1681/ASN.2011011173 PMID: 22021705

Sharma, N.; Berbari, N.F.; Yoder, B.K. Ciliary dysfunction in developmental abnormalities and diseases. *Curr. Top. Dev. Biol.*, 2008, 85, 371-427. http://dx.doi.org/10.1016/S0070-2153(08)00813-2 PMID: 19147012